More than six million Americans are living with Alzheimer’s disease — and one in three seniors dies with the disease, according to statistics from the Alzheimer’s Association. With so many different factors — genetics, lifestyle and environment — influencing a person’s risk of developing Alzheimer’s, many doctors are moving away from one-size-fits-all approaches and calling for more individualized treatments. It’s a concept known as precision medicine. And it’s what inspired a…READ MORE

World Kidney Day has been observed in early March since 2006;  in the US, March is National Kidney Month. Efforts to increase awareness of kidney health are timely, as chronic kidney disease (CKD) affected an estimated 37 million Americans in 2021. Drugs prescribed for common illnesses can increase the risk or severity of CKD. This risk comes in addition to drug-to-drug interactions (DDIs) that might also exacerbate CKD. And unfortunately,…READ MORE

In February 2022, Dr. Federico Canavosio of Integrative Medical Care (IMC) in Vero Beach, FL started applying a new approach to memory care for patients aged 60 and older. IMC began working with medical AI company uMETHOD Health to deploy RestoreU, an evidence-based care program for patients at risk of developing Alzheimer’s Disease (AD), dementia, or other cognitive issues. “Cognitive impairment and related dementias are difficult to treat because they…READ MORE

Despite our annual expressions of gratitude to our veterans for all they’ve sacrificed, we fall short when it comes to their health and well-being. In addition to cancer, diabetes, and mental-health disorders, veterans suffer from Alzheimer’s Disease (AD) and other forms of dementia at high rates. Veterans currently under a physician’s care need a comprehensive workup and a care plan that addresses the factors that drive the progression of AD.…READ MORE

NASHVILLE, Tenn., Nov. 9, 2022 /PRNewswire/ -- uMETHOD Health, a health technology company specializing in precision medicine for complex diseases, announces a partnership with PathGroup, one of largest independent laboratories in the United States. uMETHOD's AI-based care planning solution, RestoreU, pairs comprehensive testing from PathGroup with actionable treatment recommendations, aimed at lowering patient's risk of developing Alzheimer's and disease progression in its early stages. Read the full release.…READ MORE

uMETHOD Health is partnering with regional and national diagnostic laboratories and hundreds of physicians to identify and address the multiple factors that contribute to cognitive issues in seniors. The Raleigh, NC-based company produces leading-edge medical artificial intelligence (AI) and services to target complex diseases such as Alzheimer’s Disease (AD). On the 29th annual World Alzheimer’s Day, uMETHOD states there are multiple contributors involved in the progression of AD and they…READ MORE

uMETHOD Health is a technology company in Research Triangle Park, North Carolina, focused on treating the causes of com­plex diseases.  Its RestoreU METHOD uses patented artificial-intelligence (AI) software to identify the underlying factors that drive someone’s cognitive decline.  This software generates personalized care plans on how to prevent, slow, or even roll-back the progression of cognitive decline.  The software now identifies all the drugs someone may be taking that increase…READ MORE

Earlier this year the Center for Disease Control and Prevention (CDC) predicted that the burden of Alzheimer’s disease and related dementia (ADRD) in the United States is expected to double by 2060. It is predicted that Arizona has the second highest growth-rate of of Alzheimer’s disease, with cases expected to climb to 200,000 by 2025. ... Having multiple Alzheimer’s research centers & programs, some would say Arizona is at the…READ MORE

Alzheimer's disease (AD) is a progressive, neurodegenerative condition in which individuals exhibit memory loss, dementia, and impaired metabolism. Nearly all previous single-domain studies to treat AD have failed, likely because it is a complex disease with multiple underlying drivers contributing to risk, onset, and progression. Keine et al. explored the efficacy of a multidomain therapy approach based on the disease risk factor status specific to individuals with AD diagnosis or…READ MORE